Immunic (IMUX) Set to Announce Earnings on Thursday

Immunic (NASDAQ:IMUX) will be releasing its earnings data before the market opens on Thursday, November 7th. Analysts expect Immunic to post earnings of ($0.22) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same period last year, the business earned ($0.54) EPS. On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Trading Up 1.3 %

IMUX stock traded up $0.02 during midday trading on Tuesday, reaching $1.22. 603,610 shares of the company’s stock traded hands, compared to its average volume of 598,316. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $2.11. The business has a 50-day moving average price of $1.49 and a two-hundred day moving average price of $1.35.

Analyst Ratings Changes

Several research firms have commented on IMUX. B. Riley assumed coverage on Immunic in a research report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective on the stock. Piper Sandler restated an “overweight” rating and issued a $28.00 price target on shares of Immunic in a research note on Tuesday, July 16th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 9th. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Leerink Partners reiterated an “outperform” rating and set a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.20.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.